A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Sponsor
Korean Cancer Study Group
Study ID
NCT04761744
Phase
PHASE2
Status
Unknown

Conditions

  • DDR Gene Mutation
  • Metastatic Solid Tumor

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.

Study Details

A Phase II Study of Nivolumab in Patients with Genetic alterations in DNA Damage repair and response Who Progressed after Standard treatment for Metastatic Solid Cancers

Key Dates

Start date
Jun 14, 2019
Status verified
Feb 2021
Primary completion
Mar 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab

Primary Outcome Measure

Objective response rate [ Time Frame: within maximum 3 years ]

Central Contacts

Related Studies